Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab

Published:2023-06-12 Issue:9 Volume:64 Page:1583-1587
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Parisi Rose¹^ORCID,Cowen Emily A.¹,Gu Stephanie¹,Dusza Stephen¹,Pulitzer Melissa²³,Geyer Mark B.⁴^ORCID,King Amber C.⁵,Markova Alina¹³^ORCID

Affiliation:

1. Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

2. Department of Pathology and Laboratory Medicine, Dermatopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

3. Weill Cornell Medical College, Cornell University, New York, NY, USA

4. Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

5. Department of Pharmacy, Clinical Services, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Funder

NIH/NCI Cancer Center Support Grant

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2221756

Reference11 articles.

1. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia

2. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

3. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study

4. Blinatumomab for Minimal Residual Disease (MRD) in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Median Overall Survival (OS) Is Not Reached in Complete MRD Responders at a Median Follow-up of 53.1 Months

5. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3